Bavarian Nordic AS

BAVA

Equity

ISIN DK0015998017 / Valor 944279

Nasdaq Copenhagen Equities (2024-11-21)

DKK 192.45-0.31%

Bavarian Nordic AS
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Bavarian Nordic AS is a company that focuses on researching, developing, and manufacturing vaccines using viral vectors to deliver antigens for infectious diseases. The company is highly specialized in this area and has a strong track record in vaccine development. With a focus on innovation and scientific expertise, Bavarian Nordic AS plays a crucial role in the fight against infectious diseases globally.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Bavarian Nordic AS reported revenue of DKK 7,062 million for the fourth quarter of 2023. This revenue was primarily driven by DKK 5,027 million from Public Preparedness, DKK 1,877 million from Travel Health, and DKK 158 million from other revenue streams.

EBITDA Performance

The company achieved an operating result (EBITDA) of DKK 2,615 million in Q4 2023. This performance exceeded the latest guidance provided in August 2023, which had anticipated an EBITDA of DKK 2,300 million.

Profit Margins

Bavarian Nordic AS's profit margins for Q4 2023 were robust, reflecting the company's successful strategy and operational efficiency. The strong financial results underscore the company's ability to compete with other pharmaceutical companies in terms of profitability.

Outlook for 2024

For the year 2024, Bavarian Nordic AS expects revenue to be in the range of DKK 5,000-5,300 million. The anticipated revenue includes DKK 2,700–3,000 million from Public Preparedness vaccines, DKK 2,100 million from Travel Health vaccines, and approximately DKK 200 million from contract work.

Strategic Growth

Paul Chaplin, President & CEO of Bavarian Nordic AS, highlighted that the company is entering a new era with a broadened portfolio of vaccines. This strategic growth is expected to increase the company's impact on public health and establish a new base for revenue and growth in the coming years.

Summarized from source with an LLMView Source

Key figures

28.6%1Y

-37.1%3Y

49.9%5Y

Performance

47.5%1Y

60.9%3Y

56.6%5Y

Volatility